Chi‐Chung Chan

Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes

George R. Lankas, Barbara Leiting, Ranabir Sinha Roy et al. · Diabetes · 2005 · 491 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Denis Riendeau, M. David Percival, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 460 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 399 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1995 · 314 citations

Medicine, Pharmacology, Clinical Pharmacology +13